Published in AIDS Weekly, November 10th, 2003
According to published research from Germany, "A phenotypic resistance test based on recombinant expression of the active HIV protease in E. coli from patient blood samples was developed."
"The protease is purified in a rapid one-step procedure as active enzyme and tested for inhibition by five selected synthetic inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) used presently for chemotherapy of HIV-infected patients," explained D. Hoffmann and coauthors at the University of Munich.
"The HPLC system used in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2003-11-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.